📊 VRDN Key Takeaways
Is Viridian Therapeutics, Inc.\DE (VRDN) a Good Investment?
Viridian Therapeutics is a development-stage pharmaceutical company with severe ongoing cash burn (-$276.4M annually) and deeply negative profitability metrics despite recent major revenue milestone (+23,359.9% YoY). While the balance sheet provides temporary runway with $212.4M cash and low debt, current burn rate allows only ~9 months of operations without additional financing, presenting existential risk to shareholders.
Why Buy Viridian Therapeutics, Inc.\DE Stock? VRDN Key Strengths
- Massive revenue growth indicating breakthrough product approval or milestone achievement
- Strong balance sheet with $722.2M equity and minimal debt (0.03x leverage)
- Excellent liquidity position (12.65x current ratio) provides near-term financial flexibility
VRDN Stock Risks: Viridian Therapeutics, Inc.\DE Investment Risks
- Severe cash burn of -$276.4M annually with limited runway (~9 months at current burn rate)
- Extreme negative profitability metrics (Operating Margin: -512.9%, Net Margin: -483.6%) with no clear path to profitability
- Development-stage pharmaceutical exposure to regulatory, clinical, and market risks; future revenue growth uncertain and execution-dependent
Key Metrics to Watch
- Operating cash flow trend and cash runway duration
- Revenue growth sustainability and gross margin realization
- Progress on product pipeline and regulatory approvals
Viridian Therapeutics, Inc.\DE (VRDN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.65x current ratio provides a solid financial cushion.
VRDN Profit Margin, ROE & Profitability Analysis
VRDN vs Healthcare Sector: How Viridian Therapeutics, Inc.\DE Compares
How Viridian Therapeutics, Inc.\DE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Viridian Therapeutics, Inc.\DE Stock Overvalued? VRDN Valuation Analysis 2026
Based on fundamental analysis, Viridian Therapeutics, Inc.\DE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Viridian Therapeutics, Inc.\DE Balance Sheet: VRDN Debt, Cash & Liquidity
VRDN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Viridian Therapeutics, Inc.\DE's revenue has grown significantly by 2,291% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.66 indicates the company is currently unprofitable.
VRDN Revenue Growth, EPS Growth & YoY Performance
VRDN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $86.0K | -$34.6M | N/A |
| Q2 2025 | $72.0K | -$48.5M | N/A |
| Q1 2025 | $72.0K | -$48.5M | N/A |
| Q3 2024 | $72.0K | -$47.7M | $-1.09 |
| Q2 2024 | $72.0K | -$48.5M | $-1.02 |
| Q1 2024 | $72.0K | -$48.5M | $-0.79 |
| Q3 2023 | $72.0K | -$25.7M | $-0.86 |
| Q2 2023 | $72.0K | -$25.7M | $-1.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Viridian Therapeutics, Inc.\DE Dividends, Buybacks & Capital Allocation
VRDN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Viridian Therapeutics, Inc.\DE (CIK: 0001590750)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VRDN
What is the AI rating for VRDN?
Viridian Therapeutics, Inc.\DE (VRDN) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VRDN's key strengths?
Claude: Massive revenue growth indicating breakthrough product approval or milestone achievement. Strong balance sheet with $722.2M equity and minimal debt (0.03x leverage).
What are the risks of investing in VRDN?
Claude: Severe cash burn of -$276.4M annually with limited runway (~9 months at current burn rate). Extreme negative profitability metrics (Operating Margin: -512.9%, Net Margin: -483.6%) with no clear path to profitability.
What is VRDN's revenue and growth?
Viridian Therapeutics, Inc.\DE reported revenue of $70.8M.
Does VRDN pay dividends?
Viridian Therapeutics, Inc.\DE does not currently pay dividends.
Where can I find VRDN SEC filings?
Official SEC filings for Viridian Therapeutics, Inc.\DE (CIK: 0001590750) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VRDN's EPS?
Viridian Therapeutics, Inc.\DE has a diluted EPS of $-2.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VRDN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Viridian Therapeutics, Inc.\DE has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VRDN stock overvalued or undervalued?
Valuation metrics for VRDN: ROE of -47.4% (sector avg: 15%), net margin of -483.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VRDN stock in 2026?
Our dual AI analysis gives Viridian Therapeutics, Inc.\DE a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VRDN's free cash flow?
Viridian Therapeutics, Inc.\DE's operating cash flow is $-276.4M, with capital expenditures of $495.0K. FCF margin is -390.8%.
How does VRDN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -483.6% (avg: 12%), ROE -47.4% (avg: 15%), current ratio 12.65 (avg: 2).